Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 28;21(1):347.
doi: 10.1186/s12957-023-03232-1.

Long-term survival in patients with PMP: a single-institutional retrospective study from China

Rui Yang  1 , Yu-Bin Fu  1 , Xin-Bao Li  1 , Ru Ma  1 , Yan-Dong Su  1 , He-Liang Wu  2 , Xin-Li Liang  1 , Yan Li  3   4
Affiliations

Long-term survival in patients with PMP: a single-institutional retrospective study from China

Rui Yang et al. World J Surg Oncol. .

Abstract

Background: As the standard treatment for pseudomyxoma peritonei (PMP), cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly prolong the survival of PMP patients, and some patients can even achieve long-term survival (LTS) or clinical cure. The purpose of this study was to analyze the clinicopathological and treatment features of PMP patients with LTS and to explore the survival benefit factors of PMP patients.

Methods: The clinicopathological and prognostic data of PMP patients who received CRS + HIPEC at our center from December 2004 to May 2023 were retrospectively analyzed. PMP patients were divided into LTS group (≥ 10 years) and short-term survival (STS) group (< 5 years) according to the length of natural history. Univariate and multivariate analyses were performed to explore the beneficial factors of PMP patients with LTS.

Results: A total of 609 patients with PMP received CRS + HIPEC treatment at our center. Two-hundred one patients with PMP were included in the study after screening, including 39 patients (19.4%) in the LTS group and 162 patients (80.6%) in the STS group. In STS group and LTS group, median overall survival based on natural history was 29.2 (2.4-59.9) vs. 138.9 (120.3-416.7) months. Univariate analysis revealed 8 factors (P < 0.05) with statistically significant differences between the two groups: gender, chemotherapy history, previous surgical score, Karnofsky Performance Status score, pathological diagnosis, lymphatic metastasis, peritoneal cancer index, and completeness of cytoreduction (CC). Multivariate analysis identified only two factors independently associated with LTS of PMP patients: CC and pathological diagnosis.

Conclusion: Complete CRS and pathological features are two key factors affecting LTS in PMP patients.

Keywords: Completeness of cytoreduction; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Long-term survival; Pathological diagnosis; Pseudomyxoma peritonei.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Selection of PMP patients
See this image and copyright information in PMC

References

    1. Rizvi SA, Syed W, Shergill R. Approach to pseudomyxoma peritonei. World J Gastrointest Surg. 2018;10(5):49–56. doi: 10.4240/wjgs.v10.i5.49. - DOI - PMC - PubMed
    1. Morera-Ocon FJ, Navarro-Campoy C. History of pseudomyxoma peritonei from its origin to the first decades of the twenty-first century. World J Gastrointest Surg. 2019;11(9):358–364. doi: 10.4240/wjgs.v11.i9.358. - DOI - PMC - PubMed
    1. Smeenk RM, Bruin SC, van Velthuysen ML, Verwaal VJ. Pseudomyxoma peritonei. Curr Probl Surg. 2008;45(8):527–575. doi: 10.1067/j.cpsurg.2008.04.003. - DOI - PubMed
    1. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34(2):196–201. doi: 10.1016/j.ejso.2007.04.002. - DOI - PubMed
    1. Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511–519. doi: 10.1080/02656736.2017.1310938. - DOI - PubMed